REDUCTION OF ASTHMA EXACERBATIONS FOLLOWING INITIATION OF SINGLE-INHALER TRIPLE THERAPY WITH FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN US CLINICAL CARE

被引：0
|
作者：
Bogart, Michael
Germain, Guillaume
Laliberte, Francois
Mahendran, Malena
Duh, Mei S.
Dirocco, Kristi
Noorduyn, Stephen G.
Paczkowski, Rosirene
Balkissoon, Ronald C.
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.4209
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：6527A / 6528A
页数：2
相关论文
共 50 条
  • [21] Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial
    Han, M. K.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lipson, D. A.
    Lomas, D. A.
    Martinez, F. J.
    Naya, I.
    Pascoe, S. J.
    Wise, R. A.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [22] Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
    Bremner, Peter R.
    Birk, Ruby
    Brealey, Noushin
    Ismaila, Afisi S.
    Zhu, Chang-Qing
    Lipson, David A.
    RESPIRATORY RESEARCH, 2018, 19
  • [23] Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
    Peter R. Bremner
    Ruby Birk
    Noushin Brealey
    Afisi S. Ismaila
    Chang-Qing Zhu
    David A. Lipson
    Respiratory Research, 19
  • [24] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis
    Bardsley, Samuel
    Criner, Gerard J.
    Halpin, David M. G.
    Han, MeiLan K.
    Hanania, Nicola A.
    Hill, David
    Lange, Peter
    Lipson, David A.
    Martinez, Fernando J.
    Midwinter, Dawn
    Siler, Thomas M.
    Singh, Dave
    Wise, Robert A.
    Van Zyl-Smit, Richard N.
    Berkman, Neville
    RESPIRATORY MEDICINE, 2022, 205
  • [25] Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared with Tiotropium Monotherapy in Patients with Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations
    Obeid, D.
    Bansal, S.
    Brown, N.
    Compton, C.
    Corbridge, T. C.
    Dorais, K.
    Erb, D.
    Harvey, C.
    Kaisermann, M. C.
    Kaye, M.
    Lipson, D. A.
    Martin, N.
    Zhu, C. Q.
    Papi, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [26] EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON EXACERBATIONS COMPARED WITH BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD AND NO HISTORY OF EXACERBATIONS: A POST HOC ANALYSIS OF THE FULFIL STUDY
    Panettieri, Reynold
    Bangalore, Mohan
    Camargo, Carlos
    Cheema, Tariq
    El Bayadi, Sherif
    Fiel, Stanley
    Jain, Renu
    Midwinter, Dawn
    Rabadi, Nashat
    Thomashow, Byron
    Lipson, David
    CHEST, 2021, 160 (04) : 1822A - 1825A
  • [27] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [28] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 24
  • [29] Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
    Brealey, Noushin
    Gupta, Ashutosh
    Renaux, Jessica
    Mehta, Rashmi
    Allen, Ann
    Henderson, Alex
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 753 - 764
  • [30] InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
    Singh, D.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S. J.
    Wise, R. A.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345